About this trial
The goal of this study is to increase genetic education and genetic testing for hereditary cancer risk among prostate cancer survivors. The study will:
Test the effectiveness of a digital guide (DG+) vs. print guide (Print+) vs. enhanced usual care (EUC) on engagement in genetic education and uptake of genetic testing.
Evaluate the impact of the DG+ vs. Print+ vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes).
Explore the ways (methods) that influence how participants experience the intervention.
The main questions this study aims to answer are: which group - the digital guide (DG+) group, print (Print+) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education.
Participants will be randomly assigned to either the digital guide (DG+) group, the print guide (Print+) group or EUC group. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the three groups to determine which is most most likely to complete genetic testing (GT) and which group engages more with genetic education.
Eligibility criteria
Qualifiers
18-80 years of age
At least 6-months post diagnosis with prostate cancer
Have not had genetic testing for hereditary cancer
Have received care at one of the participating sites in the prior five years
Disqualifiers
Do not speak English
Unable to access the Internet
Have previously undergone germline genetic testing for hereditary cancer risk or previously had genetic counseling (GC) and declined genetic testing (GT)
Are unable to provide informed consent
Trial design
Treatments tested in this trial
- Print Genetic Education Guide
- Digital Guide Genetic Education Guide
- Enhanced Usual Care
Treatment groups
Sponsors and collaborators
Georgetown University
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Rutgers University
Collaborator